IPO registrations (S-1, F-1) · Registrants
Taysha Gene Therapies, Inc.
- SEC CIK
- 1806310 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2020-09-02, last 2020-09-18; 1 initial registration, 3 amendments
- Outcome
- Final prospectus filed 2020-09-25; declared effective 2020-09-23
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1430, Dallas, TX 75247
- EIN
- 84-3199512
- Ticker
- TSHA (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Taysha Gene Therapies, Inc. on the corporate pages
Offering terms
- Proposed price range
- $18.00–$20.00 per share (S-1/A filed 2020-09-18)
- Final price
- $20.00 per share, within the range (424B4 filed 2020-09-25, an initial public offering)
- Shares sold
- 7,869,566
- Gross proceeds
- $157,391,320 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol TSHA
- Lead underwriters
- Goldman Sachs; Morgan Stanley; Jefferies
- Syndicate
- Chardan
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: TAYSHA GENE THERAPIES, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: Taysha Gene Therapies, Inc. Fuzzy (name and state)
- Business registration: TAYSHA GENE THERAPIES, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: TAYSHA GENE THERAPIES, INC. EXACT (EIN (EXACT))
- Form D issuer: Taysha Gene Therapies, Inc. EXACT (CIK (EXACT))
- Lobbying client: TAYSHA GENE THERAPIES Fuzzy (name and state)
- Lobbying client: TAYSHA GENE THERAPIES Fuzzy (name and state)
- SEC filer: Taysha Gene Therapies, Inc. EXACT (CIK (EXACT))
Filings 8
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-09-02 | S-1 | S-1 (registration) | Taysha Gene Therapies, Inc. | 0001193125-20-238197 ↗ |
| 2020-09-08 | S-1/A | S-1/A (amendment) | Taysha Gene Therapies, Inc. | 0001193125-20-241062 ↗ |
| 2020-09-17 | S-1/A | S-1/A (amendment) | Taysha Gene Therapies, Inc. | 0001193125-20-247565 ↗ |
| 2020-09-18 | S-1/A | S-1/A (amendment) | Taysha Gene Therapies, Inc. | 0001193125-20-248359 ↗ |
| 2020-09-23 | S-1MEF | S-1MEF (added securities) | Taysha Gene Therapies, Inc. | 0001193125-20-252504 ↗ |
| 2020-09-23 | EFFECT | EFFECT (declared effective) | Taysha Gene Therapies, Inc. | 9999999995-20-002541 ↗ |
| 2020-09-25 | 424B4 | 424B4 (final prospectus) | Taysha Gene Therapies, Inc. | 0001193125-20-253550 ↗ |
| 2021-10-14 | EFFECT | EFFECT (declared effective) | Taysha Gene Therapies, Inc. | 9999999995-21-003891 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-09-18 | S-1/A | registration statement | $18.00–$20.00 | 6,578,950 | - | Nasdaq TSHA | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2020-09-25 | 424B4 | final prospectus | $20.00 | 7,869,566 | $157,391,320 | Nasdaq TSHA | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Alam Kamran | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 21 | 2020–2026 | |
| Donenberg Phillip B. | Director | 10 | 2020–2026 | ||
| Manning Paul B | Director,TenPercentOwner; TenPercentOwner | 15 | 2020–2025 | ||
| Nagendran Sukumar | Director; Director,Officer | President and Head of R&D | 18 | 2020–2026 | |
| Nolan Sean P. | Director; Director,Officer | Chief Executive Officer | 13 | 2020–2026 | |
| PRASAD SUYASH | Officer | CMO and Head of R&D | 9 | 2020–2022 | |
| Session R.A. II | Director,Officer,TenPercentOwner; Director,TenPercentOwner; TenPercentOwner | President and CEO | 9 | 2020–2023 | |
| Reape Kathleen | Director | 5 | 2020–2023 | ||
| Sepp-Lorenzino Laura | Director | 8 | 2020–2026 | ||
| Astellas Pharma Inc. | TenPercentOwner | 1 | 2022 | ||
| Audentes Therapeutics, Inc. | TenPercentOwner | 1 | 2022 | ||
| Stalfort John A III | Director | 6 | 2023–2026 | ||
| Long Alison S | Director | 5 | 2023–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2023-08-25 | Taysha Gene Therapies, Inc. | Biotechnology | $149,997,018 | $149,952,767 | 42 | 1 |
| 2022-11-07 | Taysha Gene Therapies, Inc. | Biotechnology | $30,000,000 | $30,000,000 | 1 | 1 |
| 2020-08-18 | Taysha Gene Therapies, Inc. | Biotechnology | $95,999,816 | $95,999,816 | 26 | 1 |
| 2020-05-04 | Taysha Gene Therapies, Inc. | Biotechnology | $30,000,000 | $18,000,000 | 9 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Taysha Gene Therapies, Inc. | TX | State business registries | name and state |
| Business registration | TAYSHA GENE THERAPIES, INC. | TX | State business registries | name and state |
| Business registration | TAYSHA GENE THERAPIES, INC. | TX | State business registries | name and state |
| Plan sponsor | TAYSHA GENE THERAPIES, INC. | TX | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Taysha Gene Therapies, Inc. | TX | Form D private offerings | CIK (EXACT) |
| Lobbying client | TAYSHA GENE THERAPIES | TX | Federal lobbying (LDA) | name and state |
| Lobbying client | TAYSHA GENE THERAPIES | TX | Federal lobbying (LDA) | name and state |
| SEC filer | Taysha Gene Therapies, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Taysha Gene Therapies, Inc. | TX | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | TAYSHA GENE THERAPIES, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), TX first:
- ILEX ONCOLOGY INC TX
- HEMOBIOTECH, INC. TX
- Peloton Therapeutics, Inc. TX
- Alpha Cognition Inc. TX
- Instil Bio, Inc. TX
- Kiromic Biopharma, Inc. TX
- CG Oncology, Inc. TX
- Voyager Acquisition Corp./Cayman Islands TX
- STEM CELL INNOVATIONS, INC. TX
- REPROS THERAPEUTICS INC. TX
In other datasets, the same topic (Health) in TX:
- Nonprofit: AARON ALEXANDERS CLUB NICU (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health